Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5637614 | 0.84 | CHRM1 (0.35) | HTR4MEN1KMT2ACHRM1SLC6A2 | |
| SCHEMBL5635776 | 0.82 | CHRM1 (0.33) | HTR4MEN1KMT2ACHRM1SLC6A2 | |
| SCHEMBL5635312 | 0.78 | SLC6A2 (0.34) | MEN1KMT2ACHRM1SLC6A2SLC6A4 | |
| SCHEMBL5636611 | 0.76 | CHRM3 (0.37) | HTR4MEN1KMT2ACHRM1SLC6A2 | |
| Hydrochloric Acid SCHEMBL5634885 | 0.76 | LMNA (0.35) | HTR4MEN1KMT2ACHRM1SLC6A2 | |
| SCHEMBL5635845 | 0.73 | HTR4 (0.40) | HTR4MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL6577259 | 0.72 | PSMB8 (0.33) | — | |
| SCHEMBL6574874 | 0.71 | MEN1 (0.35) | HTR4MEN1KMT2ACHRM1SLC6A2 | |
| SCHEMBL5635326 | 0.69 | HPGD (0.35) | MEN1KMT2ACHRM1SLC6A2SLC6A4 | |
| SCHEMBL5664764 | 0.69 | PDE7A (0.41) | CHRM1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148236-B2 | Modulators of acetylcholine receptors | MERCK & CO., INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20050182088-A1 | Modulators of acetylcholine receptors | MERCK SHARP & DOHME CORP. | 2005-08-18 | — | — | US | disclosed |
| EP-1472248-A1 | MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003062235-A1 | MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182088-A1 | Modulators of acetylcholine receptors | CHRM3, CHRNG, CHRM5 | HTR4 207/4885MEN1 3951/4885KMT2A 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.